The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Topline results obtained from a phase I dose escalation trial (NCT04588922) show that primary and secondary endpoints in safety, clinical activity, pharmacokinetics, and pharmacodynamics were met in patients with relapsed/refractory (R/R) lymphomas.1 These results indicate that SLS009 (formerly GFH009) may be a safe and efficacious treatment option for this patient population.1
A total of 52 R/R patients with lymphoma were enrolled and 34 patients were evaluable for efficacy. In this population:
No patients had unexpected toxicities and the drug was well tolerated, with no drug-related deaths reported at any dose level.
The topline data from this phase I dose-escalation trial have led to a phase II clinical study. This study will assess SLS009 in patients with peripheral T-cell lymphoma, further elucidating the potential of this treatment for those with hematologic malignancies who have exhausted previous treatment options.1
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content